aliases:
- Loyal
- LOY-002 canonical_name: Loyal for Dogs dashboard_url: https://dashboard.kismetpets.com/context/entities/competitor/loyal-for-dogs/ id: 20 kind: competitor last_synthesized_at: ‘2026-05-06T17:22:38.995142+00:00’ slug: loyal-for-dogs updated_at: ‘2026-05-06T17:22:38.995346+00:00’
Loyal for Dogs
Competitor — loyal-for-dogs
Not a food competitor — but a category-shaping force Kismet must track. Raised 100M Series C in 2026 (total >250M) for LOY-002, the first potential FDA-approved lifespan-extension drug for any species. STAY study enrolled 1,300+ dogs at 70+ clinics, targeting full FDA approval post-2027.
Strategic relevance: about to make “dog aging” a mainstream consumer conversation. Pre-approval, they’re already creating cultural awareness that primes consumers for longevity-adjacent food products. This is the wave Kismet rides via every-dog-year-better-year-angle and healthspan-not-lifespan-positioning — adjacent, not competing.
Tracking signals: STAY trial milestones, FDA submission news, Loyal’s marketing ramp-up. When Loyal files with FDA, expect spike in “anti-aging dog food” search volume — Kismet should have evergreen healthspan content ready. Note adjacent supplement plays already piggybacking: Cellular Longevity Inc (NMN), Leap Years (longevity supplement), Zesty Paws Healthy Aging NAD+ — all $520M anti-aging pet category, 7.9% CAGR. None of them have what Kismet has: clinical proof in a daily food format.
Aliases
- Loyal
- LOY-002